恩替卡韦和替诺福韦阿拉芬酰胺治疗慢性乙型肝炎药物依从

StephenW

J Med Virol. 2020 Jan 29. doi: 10.1002/jmv.25692. [Epub ahead of print]
Comparison of medication adherence and satisfaction between entecavir and tenofovir alafenamide therapy in chronic hepatitis B.
Tamaki N1, Kurosaki M1, Nakanishi H1, Itakura J1, Inada K1, Kirino S1, Yamashita K1, Osawa L1, Sekiguchi S1, Hayakawa Y1, Wang W1, Okada M1, Higuchi M1, Takaura K1, Maeyashiki C1, Kaneko S1, Yasui Y1, Tsuchiya K1, Takahashi Y1, Izumi N1.
Author information
Abstract

Adherence to nucleotide/nucleoside analog therapy is important in improving prognosis in chronic hepatitis B. We aimed to compare medical adherence and satisfaction with entecavir (ETV) and tenofovir alafenamide (TAF) and to assess the effect of switching from ETV to TAF. Patients taking ETV (n = 114) and TAF (n = 35), and who switched from ETV to TAF (n = 15) were included. Medication adherence and satisfaction were assessed using a questionnaire. There was no significant difference in adherence between the ETV and TAF groups, but the medication satisfaction rates (0-10, prefer-dislike) were 1.72 ± 2.2 and 0.69 ± 1.5, respectively (P = 0.01; significantly higher in the TAF group). In patients who switched from ETV to TAF, medication adherence significantly improved (P = 0.04) as follows: never forgetting, from 40%-87%; forgetting once every 2-3 months, from 33%-7%; forgetting once every 2 months, from 20%-7%, and forgetting once every 4 weeks, from 7%-0%. Similarly, the medication satisfaction rate significantly improved from 4.53 ± 3.2 to 1.27 ± 2.4 after switching (P = 0.008). In conclusion, switching from ETV to TAF can be a useful approach to improve medication adherence and satisfaction. This article is protected by copyright. All rights reserved.

This article is protected by copyright. All rights reserved.
KEYWORDS:

Anti-hepatitis B virus antivirals; Antiviral agents; Disease control; Disease controlHepatitis B virusVirus classification; sAntiviral agents

PMID:
    31994737
DOI:
    10.1002/jmv.25692